# S0833, Bortezomib, Thalidomide, Lenalidomide, Combination Chemotherapy, and Autologous Stem Cell Transplant in Treating Patients With Newly Diagnosed Multiple Myeloma

> **NCT01055301** · PHASE2 · WITHDRAWN · sponsor: **SWOG Cancer Research Network**

## Conditions studied

- Multiple Myeloma
- Plasma Cell Myeloma

## Interventions

- **DRUG:** bortezomib
- **DRUG:** cisplatin
- **DRUG:** cyclophosphamide
- **DRUG:** dexamethasone
- **DRUG:** doxorubicin hydrochloride
- **DRUG:** etoposide
- **DRUG:** lenalidomide
- **DRUG:** melphalan
- **DRUG:** thalidomide
- **GENETIC:** gene expression analysis
- **GENETIC:** microarray analysis
- **OTHER:** laboratory biomarker analysis
- **PROCEDURE:** autologous-autologous tandem hematopoietic stem cell transplantation

## Key facts

- **NCT ID:** NCT01055301
- **Lead sponsor:** SWOG Cancer Research Network
- **Sponsor class:** NETWORK
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2011-07
- **Primary completion:** 2011-07
- **Final completion:** 2011-07
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** lack of accrual
- **Last updated:** 2015-03-06

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01055301

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01055301, "S0833, Bortezomib, Thalidomide, Lenalidomide, Combination Chemotherapy, and Autologous Stem Cell Transplant in Treating Patients With Newly Diagnosed Multiple Myeloma". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01055301. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*